serena williams and glp 1 Could Williams' GLP-1 Disclosure Shift Obesity Stigma? Serena Williams' GLP-1 Shift: 34
Description
GLP-1
The reported incidence varies across specific agents and doses, with fatigue sometimes grouped with asthenia or malaise in adverse event reporting
Liraglutide (Saxenda, Victoza): Typically results in a more modest weight loss, with patients losing about 58% of their body weight over a year
Nimacimab compared favourably to and provided significant additive weight loss when combined with GLP-1-targeted drugs like tirzepatide, said Punit Dhillon, CEO of Skye
Two completely different shoppers
